Brief: AnGes submits CTN of hypertension DNA vaccine
Brief: Anges MG says exercise of options
Brief: Anges expects to apply for approval to manufacture treatment for severe blockage of the arteries in the legs - nikkei
Brief: Anges MG announces exercise of options through private placement
Brief: Anges MG receives IND approval from FDA
Table: AnGes MG -Q1 group results
Brief: AnGes MG plans cooperation with Vical Inc on development of genetic medication for Chronic Hepatitis B
Brief: AnGes MG to change name to AnGes Inc
Table: AnGes MG -2016 parent results
Table: AnGes MG -2016 group results
Brief: Anges MG announces exercise of warrants
Brief: AnGes MG announces exercise of 8,250 options
Brief: AnGes MG signs strategic business alliance agreement with Vical
Brief: AnGes MG and Morishita Jintan signs license agreement
Brief: Medikit and AnGes MG agree to terminate joint development contract
Table: AnGes MG -2016 group forecast
Table: AnGes MG -9-MTH group results
Brief: AnGes MG announces exercise of 10,300 options
Brief: AnGes MG announces exercise of 13,681 options